ts in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® and REPRONEX® (menotropins for injection, USP), Novarel® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).
Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
(1) Degarelix [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; December 2008.
(2) Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.
(3) Van Poppel H, Tombal B, de la Rosette JJ, Persson B-E, Jensen J-K, Olesen TK. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker -- results from a 1-yr, multicentre, randomised phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54(4):805-813.
(4) Doehn C. Immunotherapy of Prostate Cancer. Eur Urol. (2006);53-4:681-683.
*Lupron Depot® (leuprolide acetate for depot suspension) is a registered trademark of TAP Pharmaceuticals Inc.
SOURCE Ferring Pharmaceuticals Inc.
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Ferring Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy2
. BSGI Makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings3
. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation4
. Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients5
. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients6
. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients7
. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients8
. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes9
. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials10
. New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI11
. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors